Research progress of m6A demethylase in leukemia

doi:10.3760/cma.j.issn.1007-1245.2023.17.003

International Medicine and Health Guidance News ›› 2023, Vol. 29 ›› Issue (17): 2378-2380.DOI: 10.3760/cma.j.issn.1007-1245.2023.17.003

• New Medical Advances • Previous Articles Next Articles

Research progress of m⁶A demethylase in leukemia

Zhou Xinyu, Zhang Ting, Jia Xiuhong

Department of Pediatrics, Binzhou Medical University Hospital, Binzhou 256603, China

Received:2023-06-05 Online:2023-09-01 Published:2023-09-21
Contact: Jia Xiuhong, Email: jiaxiuhong001@163.com
Supported by:
Natural Science Foundation of Shandong Province (ZR2014HL032); Medical Health Science and Technology Development Plan Project of Shandong Province (2017WS038)

m⁶A去甲基化酶在白血病中的研究进展

周欣宇张婷贾秀红

滨州医学院附属医院儿科，滨州　256603

通讯作者: 贾秀红，Email：jiaxiuhong001@163.com
基金资助:
山东省自然科学基金（ZR2014HL032）；山东省医药卫生科技发展计划项目（2017WS038）

Abstract

Abstract:

Methylation of m6-methyladenosine purines is the most common method of RNA chemical modification, and demethylase can demethylate bases that have undergone m6A methylation modification to affect the stability of cellular mRNA. Demethylase is abnormally highly expressed in leukemia and has carcinogenic effects by modulating the stability of downstream target gene transcripts. Therefore, molecular inhibitors targeting demethylase could be developed to treat leukemia, which provides a new direction for the treatment of leukemia.

Key words:

Leukemia, RNA demethylase, FTO, ALKBH5, Progress

摘要：

N6-甲基腺苷嘌呤甲基化是最常见的RNA化学修饰，去甲基化酶可对已经发生甲基化修饰的碱基进行去甲基化进而影响细胞mRNA的稳定性。去甲基化酶在白血病中异常高表达，通过调控下游靶基因转录本的稳定性发挥致癌作用。因此，开发靶向去甲基化酶的分子抑制剂，可为白血病的治疗提供新方向。

关键词:

白血病, RNA去甲基化酶, 脂肪和肥胖相关蛋白, AlkB同源蛋白5, 进展

Zhou Xinyu, Zhang Ting, Jia Xiuhong.

Research progress of m⁶A demethylase in leukemia [J]. International Medicine and Health Guidance News, 2023, 29(17): 2378-2380.

周欣宇张婷贾秀红.

m⁶A去甲基化酶在白血病中的研究进展 [J]. 国际医药卫生导报, 2023, 29(17): 2378-2380.

References

[1] Weng H, Huang H, Chen J. RNA N 6-methyladenosine modification in normal and malignant hematopoiesis[J]. Adv Exp Med Biol, 2019, 1143:75-93. DOI: 10.1007/978-981-13-7342-8_4.
[2] Ma S, Chen C, Ji X, et al. The interplay between m6A RNA methylation and noncoding RNA in cancer[J]. J Hematol Oncol, 2019, 12(1):121. DOI: 10.1186/s13045-019- 0805-7.
[3] Deng X, Su R, Weng H, et al. RNA N6-methyladenosine modification in cancers: current status and perspectives[J]. Cell Res, 2018, 28(5):507-517. DOI: 10.1038/s41422-018-0034-6.
[4] You Y, Fu Y, Huang M, et al. Recent advances of m6A demethylases inhibitors and their biological functions in human diseases[J]. Int J Mol Sci, 2022, 23(10):5815. DOI: 10.3390/ijms23105815.
[5] Melstrom L, Chen J. RNA N6-methyladenosine modification in solid tumors: new therapeutic frontiers[J]. Cancer Gene Ther, 2020, 27(9):625-633. DOI: 10.1038/s41417-020-0160-4.
[6] Qu J, Yan H, Hou Y, et al. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential[J]. J Hematol Oncol, 2022, 15(1):8. DOI: 10.1186/s13045- 022-01224-4.
[7] Chen J, Du B. Novel positioning from obesity to cancer: FTO, an m6A RNA demethylase, regulates tumour progression[J]. J Cancer Res Clin Oncol, 2019, 145(1):19-29. DOI: 10.1007/s00432-018-2796-0.
[8] Zheng QK, Ma C, Ullah I, et al. Roles of N6-methyladenosine demethylase FTO in malignant tumors progression[J]. Onco Targets Ther, 2021, 14:4837-4846. DOI: 10.2147/OTT.S329232.
[9] Su R, Dong L, Li Y, et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion[J]. Cancer Cell, 2020, 38(1):79-96.e11. DOI: 10.1016/j.ccell.2020. 04.017.
[10] Li Z, Weng H, Su R, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase[J]. Cancer Cell, 2017, 31(1):127-141. DOI: 10.1016/j.ccell.2016.11.017.
[11] Xiao Q, Lei L, Ren J, et al. Mutant NPM1-regulated FTO-mediated m6A demethylation promotes leukemic cell survival via PDGFRB/ERK signaling axis[J]. Front Oncol, 2022, 12:817584. DOI: 10.3389/fonc.2022.817584.
[12] Qing Y, Su R, Chen J. Targeting FTO for cancer therapy and more[J]. Aging (Albany NY), 2021, 13(15):19080-19082. DOI: 10.18632/aging.203404.
[13] 吴淡森,郑彩罚,曾泳萍,等.let-7b-5p通过FTO/m6A/MYC信号通路抑制人类白血病THP-1细胞增殖[J].中国实验血液学杂志,2020,28(6):1873-1879. DOI:10.19746/j.cnki.issn1009-2137.2020.06.014.
[14] Zhang Y, Hu X, Han Y, et al. Targeting inhibition of N-6-methyladenosine demethylase Fto displays potent anti-tumor activities in chronic lymphocytic leukemia[J]. BLOOD, 2020, 136(Supplement 1):35-36. DOI:10.1182/blood-2020-139526.
[15] Deng M, Gui X, Kim J, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration[J]. Nature, 2018, 562(7728):605-609. DOI: 10.1038/s41586-018-0615-z.
[16] Luo X, Zheng D, Zheng R, et al. The platelet isoform of phosphofructokinase in acute myeloid leukemia: clinical relevance and prognostic implication[J]. BLOOD, 2018, 132(Supplement 1):5251. DOI:10.1182/blood- 2018-99- 113786.

Research progress of m⁶A demethylase in leukemia

m⁶A去甲基化酶在白血病中的研究进展

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	Wang Zechuan, Huang Yueqin. Advances in targeted drug therapy for acute myeloid leukemia [J]. International Medicine and Health Guidance News, 2023, 29(8): 1045-1048.
[2]	Xu Shijie, Luo Zebin, Chen Xiaodong. Application and progress of CT pulmonary angiography in diagnosis and treatment of pulmonary embolism [J]. International Medicine and Health Guidance News, 2023, 29(8): 1053-1056.
[3]	Zhang Heng, Pan Guangtao, Yin Ming, Zhang Ping, Yin Xia. Progress in autologous fat transplantation in plastic surgery [J]. International Medicine and Health Guidance News, 2023, 29(7): 889-892.
[4]	Wu Xuemei, Zhang Yujie, Xie Shenghua. Psoriasis and its cardiovascular system comorbidities [J]. International Medicine and Health Guidance News, 2023, 29(4): 453-456.
[5]	Yang Lina, Wang Yu, Xia Bo. Research progress on clinical application of Lao Moxibustion [J]. International Medicine and Health Guidance News, 2023, 29(2): 154-.
[6]	Yang Jia, Xi Zhefan, Zou Haozhen, Xu Qiang, Dong Hua. Research progress on new immunosuppressive agents in treatment of idiopathic membranous nephropathy [J]. International Medicine and Health Guidance News, 2023, 29(18): 2517-2521.
[7]	Xi Zhefan, Yang Jia, Zou Haozhen, Dong Hua. Application of sacubitril/valsartan in patients with heart failure taking dialysis [J]. International Medicine and Health Guidance News, 2023, 29(18): 2522-2525.
[8]	Niu Huan, Cong Chenyang. Research progress on the roles of aqueous humor inflammatory factors in the pathogenesis of diabetic macular edema [J]. International Medicine and Health Guidance News, 2023, 29(17): 2369-2372.
[9]	Luo Meijuan, Zhang Youxiang, Ou Qiaoqun, Wang Lina. Research progress and clinical application of intestinal bacteriophage and human health [J]. International Medicine and Health Guidance News, 2023, 29(17): 2373-2377.
[10]	Zhang Xinling, Gan Wenyun. Correlations between FTO expression and airway inflammation and prognosis in patients with severe asthma [J]. International Medicine and Health Guidance News, 2023, 29(17): 2398-2401.
[11]	Zhang Cui, Liu Zhen, Liu Jingyang, Shi Xinye, Liu Zhiqiang, Sun Jingwu. NLRP3 inflammasome and diabetic cardiomyopathy [J]. International Medicine and Health Guidance News, 2023, 29(16): 2221-2225.
[12]	Fang Jianfeng. Relationship between intestinal floras and metabolic diseases [J]. International Medicine and Health Guidance News, 2023, 29(16): 2225-2229.
[13]	Long Lingmei, Liu Weiwang, Wu Yuan. Risk factors of osteoporosis and fractures and application of assessment tools [J]. International Medicine and Health Guidance News, 2023, 29(16): 2230-2234.
[14]	Xu Xi, Li Xiangyang, Zhang Bo, Xiang Yuangang, Yang Pan, Zhang Zhensheng, Xu Chuanliang. Advances on prevention of venous thromboembolism in patients with bladder cancer [J]. International Medicine and Health Guidance News, 2023, 29(15): 2073-2076.
[15]	Zhao Jiahao, Shang Xue, Zhu Hui, Li Xinxi, Xu Huipu. Research progress of PI3K/AKT signaling pathway in cardiovascular disease [J]. International Medicine and Health Guidance News, 2023, 29(15): 2077-2080.